Limits...
Prognostic Impact of ABO Blood Group on the Survival in Patients with Ovarian Cancer.

Zhou J, Yang LC, He ZY, Li FY, Wu SG, Sun JY - J Cancer (2015)

Bottom Line: Univariate Cox analyses showed that blood type A was significantly associated with OS than those with non-A types (hazard ratio (HR) 2.210, 95% confidence interval (CI) 1.373-3.557, p = 0.001).Blood type A remained an independent prognostic factor for OS than those with non-A blood types in multivariate analyses (HR 2.235, 95% CI 1.360-3.674, p = 0.002).ABO blood group is associated with survival in patients with ovarian cancer, patients with blood type A had a significantly worse OS than patients with non-A blood types, especially in patients with age > 50 years.

View Article: PubMed Central - PubMed

Affiliation: 1. Xiamen Cancer Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.

ABSTRACT

Purpose: The impact of ABO blood group on the survival of patients with ovarian cancer remains uncertain. The aim of this study was to evaluate the prognostic value of the ABO blood group in ovarian cancer patients.

Methods: 256 ovarian cancer patients who received a cytoreductive surgery were retrospectively reviewed. The prognostic impact of the ABO blood group with respect to overall survival (OS) was analyzed.

Results: The median follow-up time was 57 months and the 5-year OS was 70.1%. The 5-year OS were 55.0%, 83.3%, 82.5%, and 70.0% in patients with A, B, AB, and O blood type, respectively (p = 0.003). Patients with blood type A had a poorer 5-year OS than patients with blood type non-A (55.0% vs. 75.0%, p = 0.001), especially in patients with age > 50 years (40.0% vs. 62.5%, p = 0.004). Univariate Cox analyses showed that blood type A was significantly associated with OS than those with non-A types (hazard ratio (HR) 2.210, 95% confidence interval (CI) 1.373-3.557, p = 0.001). Blood type A remained an independent prognostic factor for OS than those with non-A blood types in multivariate analyses (HR 2.235, 95% CI 1.360-3.674, p = 0.002).

Conclusion: ABO blood group is associated with survival in patients with ovarian cancer, patients with blood type A had a significantly worse OS than patients with non-A blood types, especially in patients with age > 50 years.

No MeSH data available.


Related in: MedlinePlus

Overall survival for patients with ovarian cancer with blood type A and non-A blood types in patients with FIGO stage I (A), II (B), and III (C).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4543757&req=5

Figure 4: Overall survival for patients with ovarian cancer with blood type A and non-A blood types in patients with FIGO stage I (A), II (B), and III (C).

Mentions: We examined the prognostic effect of the ABO blood type according to different age group and different FIGO stage. Significant differences in 5-year OS between the type A and non-A types ovarian cancers were observed in patients with age > 50 years (40.0% vs. 62.5%, p = 0.004) (Figure 3A). However, for age ≤50 years patients, ABO groups showed no association with OS (p = 0.611) (Figure 3B). In patients with FIGO stage II, type A tumors had worse OS than those with non-A types (5-year OS 37.5% vs. 87.3%, p < 0.001) (Figure 4B), but there was no significant difference from the OS of FIGO stage I (p = 0.118) (Figure 4A) and III (p = 0.537) (Figure 4C) according to different blood group.


Prognostic Impact of ABO Blood Group on the Survival in Patients with Ovarian Cancer.

Zhou J, Yang LC, He ZY, Li FY, Wu SG, Sun JY - J Cancer (2015)

Overall survival for patients with ovarian cancer with blood type A and non-A blood types in patients with FIGO stage I (A), II (B), and III (C).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4543757&req=5

Figure 4: Overall survival for patients with ovarian cancer with blood type A and non-A blood types in patients with FIGO stage I (A), II (B), and III (C).
Mentions: We examined the prognostic effect of the ABO blood type according to different age group and different FIGO stage. Significant differences in 5-year OS between the type A and non-A types ovarian cancers were observed in patients with age > 50 years (40.0% vs. 62.5%, p = 0.004) (Figure 3A). However, for age ≤50 years patients, ABO groups showed no association with OS (p = 0.611) (Figure 3B). In patients with FIGO stage II, type A tumors had worse OS than those with non-A types (5-year OS 37.5% vs. 87.3%, p < 0.001) (Figure 4B), but there was no significant difference from the OS of FIGO stage I (p = 0.118) (Figure 4A) and III (p = 0.537) (Figure 4C) according to different blood group.

Bottom Line: Univariate Cox analyses showed that blood type A was significantly associated with OS than those with non-A types (hazard ratio (HR) 2.210, 95% confidence interval (CI) 1.373-3.557, p = 0.001).Blood type A remained an independent prognostic factor for OS than those with non-A blood types in multivariate analyses (HR 2.235, 95% CI 1.360-3.674, p = 0.002).ABO blood group is associated with survival in patients with ovarian cancer, patients with blood type A had a significantly worse OS than patients with non-A blood types, especially in patients with age > 50 years.

View Article: PubMed Central - PubMed

Affiliation: 1. Xiamen Cancer Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.

ABSTRACT

Purpose: The impact of ABO blood group on the survival of patients with ovarian cancer remains uncertain. The aim of this study was to evaluate the prognostic value of the ABO blood group in ovarian cancer patients.

Methods: 256 ovarian cancer patients who received a cytoreductive surgery were retrospectively reviewed. The prognostic impact of the ABO blood group with respect to overall survival (OS) was analyzed.

Results: The median follow-up time was 57 months and the 5-year OS was 70.1%. The 5-year OS were 55.0%, 83.3%, 82.5%, and 70.0% in patients with A, B, AB, and O blood type, respectively (p = 0.003). Patients with blood type A had a poorer 5-year OS than patients with blood type non-A (55.0% vs. 75.0%, p = 0.001), especially in patients with age > 50 years (40.0% vs. 62.5%, p = 0.004). Univariate Cox analyses showed that blood type A was significantly associated with OS than those with non-A types (hazard ratio (HR) 2.210, 95% confidence interval (CI) 1.373-3.557, p = 0.001). Blood type A remained an independent prognostic factor for OS than those with non-A blood types in multivariate analyses (HR 2.235, 95% CI 1.360-3.674, p = 0.002).

Conclusion: ABO blood group is associated with survival in patients with ovarian cancer, patients with blood type A had a significantly worse OS than patients with non-A blood types, especially in patients with age > 50 years.

No MeSH data available.


Related in: MedlinePlus